Azenosertib Clinical Trials
5 recruitingDrug
Phase 12Early Phase 11Phase 21Phase 31
Showing 1–5 of 5 trials
Recruiting
Phase 3
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
Ovarian Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc420 enrolled58 locationsNCT07546500
Recruiting
Phase 1
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+10 more
National Cancer Institute (NCI)48 enrolled1 locationNCT06364410
Recruiting
Phase 1
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
Solid TumorFallopian Tube CancerEpithelial Ovarian Cancer+1 more
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc172 enrolled24 locationsNCT04516447
Recruiting
Phase 2
Azenosertib in Uterine Serous Carcinoma: Biomarker Study
Uterine CancerUterine Serous CarcinomaUterine Carcinoma
Joyce Liu, MD25 enrolled2 locationsNCT06369155
Recruiting
Early Phase 1
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
Stage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8+5 more
OHSU Knight Cancer Institute90 enrolled1 locationNCT04005690